Literature DB >> 23752516

Epidemiology and risk factors for isolation of Escherichia coli producing CTX-M-type extended-spectrum β-lactamase in a large U.S. Medical Center.

Kayoko Hayakawa1, Sureka Gattu, Dror Marchaim, Ashish Bhargava, Mohan Palla, Khaled Alshabani, Uma Mahesh Gudur, Harish Pulluru, Pradeep Bathina, Pranathi Rao Sundaragiri, Moumita Sarkar, Hari Kakarlapudi, Balaji Ramasamy, Priyanka Nanjireddy, Shah Mohin, Meenakshi Dasagi, Satya Datla, Vamsi Kuchipudi, Swetha Reddy, Shobha Shahani, Vijaya Upputuri, Satya Marrey, Vedavyas Gannamani, Nandhini Madhanagopal, Srinadh Annangi, Busani Sudha, Kalyan Srinivas Muppavarapu, Judy A Moshos, Paul R Lephart, Jason M Pogue, Karen Bush, Keith S Kaye.   

Abstract

A case-case-control study was conducted to identify independent risk factors for recovery of Escherichia coli strains producing CTX-M-type extended-spectrum β-lactamases (CTX-M E. coli) within a large Southeastern Michigan medical center. Unique cases with isolation of ESBL-producing E. coli from February 2010 through July 2011 were analyzed by PCR for blaCTX-M, blaTEM, and blaSHV genes. Patients with CTX-M E. coli were compared to patients with E. coli strains not producing CTX-M-type ESBLs (non-CTX-M E. coli) and uninfected controls. Of 575 patients with ESBL-producing E. coli, 491 (85.4%) isolates contained a CTX-M ESBL gene. A total of 319 (84.6%) patients with CTX-M E. coli (282 [74.8%] CTX-M-15 type) were compared to 58 (15.4%) non-CTX-M E. coli patients and to uninfected controls. Independent risk factors for CTX-M E. coli isolation compared to non-CTX-M E. coli included male gender, impaired consciousness, H2 blocker use, immunosuppression, and exposure to penicillins and/or trimethoprim-sulfamethoxazole. Compared to uninfected controls, independent risk factors for isolation of CTX-M E. coli included presence of a urinary catheter, previous urinary tract infection, exposure to oxyimino-cephalosporins, dependent functional status, non-home residence, and multiple comorbid conditions. Within 48 h of admission, community-acquired CTX-M E. coli (n = 51 [16%]) and non-CTX-M E coli (n = 11 [19%]) strains were isolated from patients with no recent health care contacts. CTX-M E. coli strains were more resistant to multiple antibiotics than non-CTX-M E. coli strains. CTX-M-encoding genes, especially bla(CTX-M-15) type, represented the most common ESBL determinants from ESBL-producing E. coli, the majority of which were present upon admission. Septic patients with risk factors for isolation of CTX-M E. coli should be empirically treated with appropriate agents. Regional infection control efforts and judicious antibiotic use are needed to control the spread of these organisms.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23752516      PMCID: PMC3719715          DOI: 10.1128/AAC.02516-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  33 in total

Review 1.  Current trends in culture-based and molecular detection of extended-spectrum-β-lactamase-harboring and carbapenem-resistant Enterobacteriaceae.

Authors:  Muriel Gazin; Fabienne Paasch; Herman Goossens; Surbhi Malhotra-Kumar
Journal:  J Clin Microbiol       Date:  2012-01-18       Impact factor: 5.948

2.  Risk factors and outcome of extended-spectrum β-lactamase-producing Enterobacter cloacae bloodstream infections.

Authors:  Zubair A Qureshi; David L Paterson; Diana L Pakstis; Jennifer M Adams-Haduch; Gabriel Sandkovsky; Emilia Sordillo; Bruce Polsky; Anton Y Peleg; Manveen K Bhussar; Yohei Doi
Journal:  Int J Antimicrob Agents       Date:  2010-11-13       Impact factor: 5.283

3.  Molecular characteristics of extended-spectrum beta-lactamase-producing Escherichia coli from the Chicago area: high prevalence of ST131 producing CTX-M-15 in community hospitals.

Authors:  Gisele Peirano; Mike Costello; Johann D D Pitout
Journal:  Int J Antimicrob Agents       Date:  2010-03-31       Impact factor: 5.283

Review 4.  Extended-spectrum [beta]-lactamase producing Escherichia coli: changing epidemiology and clinical impact.

Authors:  Jesús Oteo; María Pérez-Vázquez; José Campos
Journal:  Curr Opin Infect Dis       Date:  2010-08       Impact factor: 4.915

Review 5.  Genetic evolution and clinical impact in extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae.

Authors:  Yong Chong; Yoshikiyo Ito; Tomohiko Kamimura
Journal:  Infect Genet Evol       Date:  2011-06-12       Impact factor: 3.342

6.  Cephalosporin and fluoroquinolone combinations are highly associated with CTX-M β-lactamase-producing Escherichia coli: a case-control study in a French teaching hospital.

Authors:  P Cassier; S Lallechère; S Aho; K Astruc; C Neuwirth; L Piroth; P Chavanet
Journal:  Clin Microbiol Infect       Date:  2011-04-12       Impact factor: 8.067

Review 7.  Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain.

Authors:  Benjamin A Rogers; Hanna E Sidjabat; David L Paterson
Journal:  J Antimicrob Chemother       Date:  2010-11-16       Impact factor: 5.790

8.  Molecular epidemiological analysis of Escherichia coli sequence type ST131 (O25:H4) and blaCTX-M-15 among extended-spectrum-β-lactamase-producing E. coli from the United States, 2000 to 2009.

Authors:  James R Johnson; Carl Urban; Scott J Weissman; James H Jorgensen; James S Lewis; Glen Hansen; Paul H Edelstein; Ari Robicsek; Timothy Cleary; Javier Adachi; David Paterson; John Quinn; Nancy D Hanson; Brian D Johnston; Connie Clabots; Michael A Kuskowski
Journal:  Antimicrob Agents Chemother       Date:  2012-02-21       Impact factor: 5.191

9.  Community-associated extended-spectrum β-lactamase-producing Escherichia coli infection in the United States.

Authors:  Yohei Doi; Yoon Soo Park; Jesabel I Rivera; Jennifer M Adams-Haduch; Ameet Hingwe; Emilia M Sordillo; James S Lewis; Wanita J Howard; Laura E Johnson; Bruce Polsky; James H Jorgensen; Sandra S Richter; Kathleen A Shutt; David L Paterson
Journal:  Clin Infect Dis       Date:  2012-11-13       Impact factor: 9.079

Review 10.  Plasmid-mediated resistance in Enterobacteriaceae: changing landscape and implications for therapy.

Authors:  Constance Schultsz; Suzanne Geerlings
Journal:  Drugs       Date:  2012-01-01       Impact factor: 11.431

View more
  22 in total

1.  In vitro activity of ceftolozane-tazobactam as determined by broth dilution and agar diffusion assays against recent U.S. Escherichia coli isolates from 2010 to 2011 carrying CTX-M-type extended-spectrum β-lactamases.

Authors:  Mark Estabrook; Brianne Bussell; Susan L Clugston; Karen Bush
Journal:  J Clin Microbiol       Date:  2014-08-20       Impact factor: 5.948

2.  Fecal ESBL Escherichia coli carriage as a risk factor for bacteremia in patients with hematological malignancies.

Authors:  Patricia Cornejo-Juárez; Juan Antonio Suárez-Cuenca; Patricia Volkow-Fernández; Jesús Silva-Sánchez; Humberto Barrios-Camacho; Esmeralda Nájera-León; Consuelo Velázquez-Acosta; Diana Vilar-Compte
Journal:  Support Care Cancer       Date:  2015-05-27       Impact factor: 3.603

3.  Epidemiology of urinary tract infections, bacterial species and resistances in primary care in France.

Authors:  A Malmartel; C Ghasarossian
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-01-06       Impact factor: 3.267

4.  Simultaneous gut colonisation and infection by ESBL-producing Escherichia coli in hospitalised patients.

Authors:  Johny Asir; Shashikala Nair; Sheela Devi; Kenchappa Prashanth; Rajagopalan Saranathan; Reba Kanungo
Journal:  Australas Med J       Date:  2015-06-30

5.  [Prevalence and risk factors for extended-spectrum β-lactamase-producing Escherichia coli causing community-onset urinary tract infections in Colombia].

Authors:  Victor M Blanco; Juan J Maya; Adriana Correa; Marcela Perenguez; Juan S Muñoz; Gabriel Motoa; Christian J Pallares; Fernando Rosso; Lorena Matta; Yamile Celis; Martha Garzon; María V Villegas
Journal:  Enferm Infecc Microbiol Clin       Date:  2016-01-13       Impact factor: 1.731

6.  Epidemiological and clinical features for cefepime heteroresistant Escherichia coli infections in Southwest China.

Authors:  W Ma; J Sun; S Yang; L Zhang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-01-27       Impact factor: 3.267

7.  Molecular characteristics of the new emerging global clone ST1193 among clinical isolates of Escherichia coli from neonatal invasive infections in China.

Authors:  Yijun Ding; Jinjing Zhang; Kaihu Yao; Wei Gao; Yajuan Wang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-10-28       Impact factor: 3.267

8.  Prevalence of bla CTX-M Genes in Gram-Negative Bloodstream Isolates across 66 Hospitals in the United States.

Authors:  Pranita D Tamma; Tiffeny T Smith; Ayomikun Adebayo; Sara M Karaba; Emily Jacobs; Teresa Wakefield; Kelly Nguyen; Natalie N Whitfield; Patricia J Simner
Journal:  J Clin Microbiol       Date:  2021-05-19       Impact factor: 5.948

9.  Dominance of CTX-M-type extended-spectrum β-lactamase (ESBL)-producing Escherichia coli isolated from patients with community-onset and hospital-onset infection in China.

Authors:  Shu Xia; Xin Fan; Zengguang Huang; Liang Xia; Meng Xiao; Rongchang Chen; Yingchun Xu; Chao Zhuo
Journal:  PLoS One       Date:  2014-07-01       Impact factor: 3.240

10.  Predictors of hospital surface contamination with Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: patient and organism factors.

Authors:  Joshua T Freeman; Jessica Nimmo; Eva Gregory; Audrey Tiong; Mary De Almeida; Gary N McAuliffe; Sally A Roberts
Journal:  Antimicrob Resist Infect Control       Date:  2014-02-04       Impact factor: 4.887

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.